Sunshine Biopharma’s wholly owned Canadian subsidiary, Nora Pharma, has launched Pravastatin, a generic prescription drug in the therapeutic class of Lipid Metabolism Regulators.

Pravastatin, the generic version of Pravachol, is a statin medication that helps lower bad cholesterol (LDL) and increase good cholesterol (HDL) in the blood, thereby reducing the risk of heart attacks, strokes and other serious cardiovascular conditions.

Nora Pharma's Pravastatin is available in strengths of 10 mg, 20 mg, and 40 mg, and comes in bottles of 100 tablets.

"We are excited to introduce Pravastatin to the market," said Steve Slilaty, CEO of Sunshine Biopharma, adding that the launch reinforces their dedication to improving patient outcomes through innovative therapies that address critical health needs.

According to IQVIA, the Canadian market for cholesterol-lowering drugs is projected to reach USD 582 million by the end of 2025 and grow at a CAGR of 8 percent, surpassing USD 1.07 billion by 2033. Globally, BioSpace estimates the lipid-lowering drugs market to exceed USD 46.58 billion by 2033.

Headquartered in Fort Lauderdale, Florida (USA), Sunshine Biopharma develops and markets life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. The company operates two wholly owned subsidiaries in Canada: Nora Pharma and Sunshine Biopharma Canada.

Currently, Sunshine Biopharma offers 74 generic prescription drugs in the Canadian market, with more than 12 additional drugs scheduled to be launched in 2026.

In addition to its generics portfolio, Sunshine Biopharma is advancing the development of its proprietary drugs: K1.1 mRNA, a lipid nano-particle (LNP) targeted for liver cancer, and SBFM-PL4, a protease inhibitor for the treatment of SARS Coronavirus infections.